Latest from Tom Gallen
Gains for its Intimate Wellness portfolio - including a strong showing from Durex - helped offset lower sales of Reckitt's OTC cold & flu remedies in Q1. CEO Kris Licht shared his thoughts on the impact of US tariffs on the business and planned future divestments.
Swedish producer of antioxidant astaxanthin AstaReal has expanded its product offering with cardiovascular health focused-brand Kyolic.
Major Europe-based consumer health players Haleon, Reckitt and Bayer feature in this sales and earnings preview, which highlights what to look out for as these three firms report their Q1 2025 results over the coming weeks.
Iron supplements specialist PharmaNutra has penned distribution deals to take its products to additional markets across the Americas and the Middle East & North Africa.
The US launch of Eroxon ED treatment by Haleon helped Futura Medical record its first ever profit in 2024. The UK firm will now look to capitalize this by seeking US and EU approval for a more potent Eroxon line extension.
Azelis adds dietary supplement ingredients and a large customer base across Spain to its portfolio with the acquisition of Solchem Nature.